ACRS News and Press, Aclaris Therapeutics Inc. From 01/10/24

2024-01-10 15:09:26 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris posts topline data from mid-stage trial for eczema therapy Aclaris to slash 46% of workforce as it reprioritizes drug programs Se...

2024-01-10 10:00:10 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and utilities could perform better in 2024 - analyst For further details see: See...

2024-01-10 07:53:46 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris to slash 46% of workforce as it reprioritizes drug programs Aclaris Therapeutics announces patent license agreement with Sun Pharma for a...

- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) --...

2023-12-20 10:00:08 ET More on Health Care Select Sector SPDR XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble For further details see: ...

2023-12-19 17:07:01 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics announces patent license agreement with Sun Pharma ...

- ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS),...

2023-12-18 15:30:01 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for ACRS on December 18, 2023 04:01PM ET. The previous analyst recommendation was Underperform. ACRS was trading at $0.9377 at issue of the analyst recommendation. The overall analyst conse...

2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...

2023-12-06 14:48:10 ET Penny Stocks – How News Makes These Small Caps Soar or Plunge Penny stocks , securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks require...